SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

By B. Bennett, D. Sasaki, B. Murray, E. O'leary, S. Sakata, Weiming Xu, J. Leisten, Aparna Motiwala, S. Pierce, Y. Satoh* and 3 more. Proceedings of the National Academy of Sciences of the United States of America, 2001

2,662 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/cd5d32049491a677fd64e9fe0c188a34ee400e46

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. (2003, methodology): “SP600125-treatment did not completely prevent the suppression of CYP7A1 by FGF-19, suggesting the existence of additional JNK-independent CYP7A1 regulatory pathways.”
A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia (2003, background): “This level of specificity is far above those achieved with other small chemical inhibitors of the enzym”
Ras and Rap control AMPA receptor trafficking during synaptic plasticity. (2002, background): “Some of the cellular processes regulated by delivered LTD-inducing stimuli and recorded from neurons expressing Rap(dn)-GFP as well as from nearbythe c-Jun amino-terminal kinase group of MAPK (JNK) and p38 MAPK signaling pathways are similar (Ip and control neurons.”
Targeting JNK for therapeutic benefit: from junk to gold? (2003, background): “SP-600125 was reported as a selective inhibitor of JNKs 1, 2 and 3 ( IC 50 = 110–150 nM), but with much less activity against the closely related p38 MAPK (IC 50 >30 μM”
Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis (2012, methodology): “Bennett BL, et al. (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.”
Nonprimed and DYRK1A-primed GSK3β-phosphorylation sites on MAP1B regulate microtubule dynamics in growing axons (2009, background): “(A) Representative immunoblots of samples from cortical cultures treated with NaCl (20 mM; Control), dimethyl sulphoxide (DMSO Control, 0.2%), LiCl (20 mM), TDZD-8 (5 μM), SP600125 (10 μM), LiCl and SP600125 (10 mM and 10 μM, respectively) or purvalanol (10 μM) and probed with the pAbs BUGS or Super”
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases (2011, methodology): “With regard to JNK inhibitors, two reversible ATP-competitive inhibitors have been widely used in the last decade, namely, SP600125 (also known as JNK inhibitor II) (22) and AS601245 (JNK inhibitor V) (46).”
The specificities of protein kinase inhibitors: an update. (2003, background): “c-Jun N-terminal kinase (JNK) inhibitor SP 600125 The compound SP 600125 was developed as an inhibitor of JNK, a member of the MAPK family [ 20 ].”